{"id":90463,"date":"2026-05-20T18:13:39","date_gmt":"2026-05-20T12:43:39","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=90463"},"modified":"2026-05-20T18:13:40","modified_gmt":"2026-05-20T12:43:40","slug":"laurus-labs-analyst-review-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/","title":{"rendered":"Laurus Labs Analyst Review May 2026"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p>This <strong><a href=\"https:\/\/univest.in\/user\/stocks\/lauruslabs\/laurus-labs-ltd-share-price-today\">Laurus Labs<\/a> analyst review<\/strong> for May 2026 covers the key data investors need for LAURUSLABS at its current price of Rs 1,325.00. Laurus Labs (NSE: LAURUSLABS) is a leading pharma company specialising in APIs, generic formulations, and CDMO services with a market capitalisation of approximately Rs 61,300 crore. The analyst consensus target of Rs 1,650 implies meaningful upside, and this <strong>Laurus Labs analyst review<\/strong> examines technical levels, business performance, valuation, and key risks that will determine whether LAURUSLABS achieves that target through FY27.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/#Laurus_Labs_Company_Snapshot_May_2026\" title=\"Laurus Labs Company Snapshot May 2026\">Laurus Labs Company Snapshot May 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/#Analyst_Insight_in_This_Laurus_Labs_Analyst_Review\" title=\"Analyst Insight in This Laurus Labs Analyst Review\">Analyst Insight in This Laurus Labs Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/#Technical_Analysis_in_This_Laurus_Labs_Analyst_Review\" title=\"Technical Analysis in This Laurus Labs Analyst Review\">Technical Analysis in This Laurus Labs Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/#Key_Support_and_Resistance_Levels\" title=\"Key Support and Resistance Levels\">Key Support and Resistance Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/#Business_Segment_Analysis\" title=\"Business Segment Analysis\">Business Segment Analysis<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/#APIs_ARV_and_Non-ARV_%E2%80%93_Large_Scale_Manufacturing\" title=\"APIs (ARV and Non-ARV &#8211; Large Scale Manufacturing)\">APIs (ARV and Non-ARV &#8211; Large Scale Manufacturing)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/#Generic_Formulations_US_Oral_Solid_Dosage\" title=\"Generic Formulations (US Oral Solid Dosage)\">Generic Formulations (US Oral Solid Dosage)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/#CDMO_Synthesis_for_Global_Pharma_Innovators\" title=\"CDMO Synthesis for Global Pharma Innovators\">CDMO Synthesis for Global Pharma Innovators<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/#Valuation_in_This_Laurus_Labs_Analyst_Review\" title=\"Valuation in This Laurus Labs Analyst Review\">Valuation in This Laurus Labs Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/#Trade_Outlook_for_Laurus_Labs\" title=\"Trade Outlook for Laurus Labs\">Trade Outlook for Laurus Labs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/#Key_Risks_for_Laurus_Labs_in_FY27\" title=\"Key Risks for Laurus Labs in FY27\">Key Risks for Laurus Labs in FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/#Conclusion_Laurus_Labs_Analyst_Review_Verdict_for_2026\" title=\"Conclusion: Laurus Labs Analyst Review Verdict for 2026\">Conclusion: Laurus Labs Analyst Review Verdict for 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/#Frequently_Asked_Questions_Laurus_Labs_Analyst_Review_2026\" title=\"Frequently Asked Questions: Laurus Labs Analyst Review 2026\">Frequently Asked Questions: Laurus Labs Analyst Review 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/#What_is_the_analyst_target_for_Laurus_Labs_in_2026\" title=\"What is the analyst target for Laurus Labs in 2026?\">What is the analyst target for Laurus Labs in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/#Is_Laurus_Labs_a_good_investment_at_Rs_132500\" title=\"Is Laurus Labs a good investment at Rs 1,325.00?\">Is Laurus Labs a good investment at Rs 1,325.00?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/#What_is_Laurus_Labss_52-week_high_and_low\" title=\"What is Laurus Labs&#8217;s 52-week high and low?\">What is Laurus Labs&#8217;s 52-week high and low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/#What_are_the_key_risks_for_Laurus_Labs\" title=\"What are the key risks for Laurus Labs?\">What are the key risks for Laurus Labs?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/laurus-labs-analyst-review-2026\/#Where_can_I_track_live_data_for_Laurus_Labs\" title=\"Where can I track live data for Laurus Labs?\">Where can I track live data for Laurus Labs?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Laurus_Labs_Company_Snapshot_May_2026\"><\/span><strong>Laurus Labs Company Snapshot May 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Laurus&#8217;s ARV API dominance for sub-Saharan Africa markets, US oral solid dosage formulations via Laurus Generics, and the CDMO synthesis business for global innovator clients are the three distinct high-quality growth pillars. The table below summarises the key data referenced in this <strong>Laurus Labs analyst review<\/strong>.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>LAURUSLABS<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharmaceuticals &#8211; APIs and CDMO<\/td>\n<\/tr>\n<tr>\n<td>CMP (May 2026)<\/td>\n<td>Rs 1,325.00<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 1,327.90<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 584.50<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 61,300 Crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing P\/E<\/td>\n<td>65x<\/td>\n<\/tr>\n<tr>\n<td>Analyst Consensus Target<\/td>\n<td>Rs 1,650<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 2,100<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 1,050<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Analyst_Insight_in_This_Laurus_Labs_Analyst_Review\"><\/span><strong>Analyst Insight in This Laurus Labs Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Associate Director <strong>Kunal Singla<\/strong> suggests watching Laurus Labs closely in May 2026. At Rs 1,325.00, Kunal Singla flags Pharmaceuticals &#8211; APIs and CDMO sector dynamics as the primary driver for LAURUSLABS&#8217;s near-term price action. He notes support in the Rs 596 to Rs 1259 zone and flags any sustained close above Rs 1404 as a positive signal worth tracking. Kunal Singla&#8217;s perspective on Laurus Labs adds professional analysis to this <strong>Laurus Labs analyst review<\/strong> and is not a buy recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Technical_Analysis_in_This_Laurus_Labs_Analyst_Review\"><\/span><strong>Technical Analysis in This Laurus Labs Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 1,325.00, LAURUSLABS is trading within its 52-week band of Rs 584.50 to Rs 1,327.90. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.<\/p>\n<p>Near-term support is identified in the Rs 596 to Rs 1259 band while resistance is seen in the Rs 1404 to Rs 1488 zone. A sustained move above Rs 1404 could open the path toward the analyst consensus target of Rs 1,650.<\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Screen the best stocks on the Univest Screener.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Support_and_Resistance_Levels\"><\/span><strong>Key Support and Resistance Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Support Zone:<\/strong> Rs 596 to Rs 1259 &#8211; investors tracking this <strong>Laurus Labs analyst review<\/strong> should watch for stabilisation or a bounce in this range as a potential accumulation signal for LAURUSLABS.<\/li>\n<li><strong>Resistance Zone:<\/strong> Rs 1404 to Rs 1488 &#8211; a sustained close above Rs 1404 would be a positive breakout signal worth flagging in this <strong>Laurus Labs analyst review<\/strong>.<\/li>\n<li><strong>Medium-Term Target:<\/strong> The analyst consensus of Rs 1,650 represents the base-case upside scenario identified in this <strong>Laurus Labs analyst review<\/strong>.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Business_Segment_Analysis\"><\/span><strong>Business Segment Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"APIs_ARV_and_Non-ARV_%E2%80%93_Large_Scale_Manufacturing\"><\/span><strong>APIs (ARV and Non-ARV &#8211; Large Scale Manufacturing)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This is the primary revenue and margin driver for Laurus Labs, directly supporting the earnings trajectory toward the consensus target of Rs 1,650.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Generic_Formulations_US_Oral_Solid_Dosage\"><\/span><strong>Generic Formulations (US Oral Solid Dosage)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This segment adds scale and diversification to Laurus Labs&#8217;s business model and is a meaningful EPS contributor through FY27 and FY28.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"CDMO_Synthesis_for_Global_Pharma_Innovators\"><\/span><strong>CDMO Synthesis for Global Pharma Innovators<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This represents the medium-term growth frontier for Laurus Labs and a key re-rating catalyst for the stock over the next 12 to 24 months.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_in_This_Laurus_Labs_Analyst_Review\"><\/span><strong>Valuation in This Laurus Labs Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 1,325.00, Laurus Labs trades at a trailing P\/E of 65x. This <strong>Laurus Labs analyst review<\/strong> presents three valuation scenarios: a bull case of Rs 2,100 on strong earnings delivery and sector tailwinds, a base case of Rs 1,650 at analyst consensus, and a bear case of Rs 1,050 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this <strong>Laurus Labs analyst review<\/strong>.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target Price<\/th>\n<th>Key Condition<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 2,100<\/td>\n<td>Strong earnings delivery and sector re-rating<\/td>\n<\/tr>\n<tr>\n<td>Base Case (Consensus)<\/td>\n<td>Rs 1,650<\/td>\n<td>Moderate growth, analyst consensus estimate<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 1,050<\/td>\n<td>Earnings miss or macro headwinds<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Trade_Outlook_for_Laurus_Labs\"><\/span><strong>Trade Outlook for Laurus Labs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Based on the technical and fundamental analysis in this <strong>Laurus Labs analyst review<\/strong>, investors might watch LAURUSLABS near the support zone of Rs 596 to Rs 1259 for potential opportunities. A flag above Rs 1404 could suggest improving momentum toward Rs 1,650. This article uses watch-and-flag language only and does not constitute a trade recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_Laurus_Labs_in_FY27\"><\/span><strong>Key Risks for Laurus Labs in FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A well-rounded <strong>Laurus Labs analyst review<\/strong> must assess downside risks. Key risks for Laurus Labs include a macro slowdown affecting Pharmaceuticals &#8211; APIs and CDMO sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in LAURUSLABS.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get daily stock recommendations and expert research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_Laurus_Labs_Analyst_Review_Verdict_for_2026\"><\/span><strong>Conclusion: Laurus Labs Analyst Review Verdict for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This <strong>Laurus Labs analyst review<\/strong> concludes that at Rs 1,325.00, LAURUSLABS offers a defined risk-reward with a consensus target of Rs 1,650. The 52-week range of Rs 584.50 to Rs 1,327.90 provides context on the current entry point. Use this <strong>Laurus Labs analyst review<\/strong> as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on LAURUSLABS.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_Laurus_Labs_Analyst_Review_2026\"><\/span><strong>Frequently Asked Questions: Laurus Labs Analyst Review 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_analyst_target_for_Laurus_Labs_in_2026\"><\/span><strong>What is the analyst target for Laurus Labs in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The analyst consensus target is Rs 1,650, with a bull case of Rs 2,100 and a bear case of Rs 1,050. Monitor Q1 FY27 earnings for confirmation as highlighted in this <strong>Laurus Labs analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Laurus_Labs_a_good_investment_at_Rs_132500\"><\/span><strong>Is Laurus Labs a good investment at Rs 1,325.00?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 1,325.00 with a P\/E of 65x and a consensus target of Rs 1,650, this <strong>Laurus Labs analyst review<\/strong> is constructive for medium to long-term investors in the Pharmaceuticals &#8211; APIs and CDMO sector. Always consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Laurus_Labss_52-week_high_and_low\"><\/span><strong>What is Laurus Labs&#8217;s 52-week high and low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 52-week high is Rs 1,327.90 and the 52-week low is Rs 584.50. At Rs 1,325.00, LAURUSLABS is positioned within this range as noted in this <strong>Laurus Labs analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_for_Laurus_Labs\"><\/span><strong>What are the key risks for Laurus Labs?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals &#8211; APIs and CDMO sector as assessed in this <strong>Laurus Labs analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_track_live_data_for_Laurus_Labs\"><\/span><strong>Where can I track live data for Laurus Labs?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track Laurus Labs&#8217;s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this <strong>Laurus Labs analyst review<\/strong>.<\/p>\n<p><em>Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Laurus Labs analyst review 2026: CMP Rs 1,325.00, MCap Rs 61,300 Cr, PE 65x. Pharmaceuticals &#8211; APIs and CDMO outlook and technical levels. May 2026.<\/p>\n","protected":false},"author":26,"featured_media":93341,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-90463","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1779281055:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["82"],"rank_math_focus_keyword":["Laurus Labs Analyst Review"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"rank_math_title":["Laurus Labs Analyst Review 2026: Key Levels and Outlook"],"rank_math_description":["Laurus Labs analyst review 2026: CMP Rs 1,325.00, MCap Rs 61,300 Cr, PE 65x. Pharmaceuticals - APIs and CDMO outlook and technical levels. May 2026."],"_wp_old_date":["2026-05-18"],"_thumbnail_id":["93341"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["12600"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/20181322\/Laurus-Labs-Analyst-Review-May-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/90463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=90463"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/90463\/revisions"}],"predecessor-version":[{"id":93342,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/90463\/revisions\/93342"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/93341"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=90463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=90463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=90463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}